THE European Medicines Agency (EMA) has released its 2024 annual report, with headline figures including the recommendation of 114 medicines for marketing authorisation, of which 46 were new active substances.
The EMA singled out some of the 46 as representing significant progress in their therapeutic areas:
* Emblaveo (aztreonam and avibactam), an antibiotic used for complicated infections, hospital-acquired pneumonia, and aerobic gram-negative bacteria;
* Eurneffy (adrenaline) in a nasal spray form for treating anaphylaxis;
* Voydeya (danicopan) is used to treat paroxysmal nocturnal haemoglobinuria (PNH), a disease in which excessive breakdown of blood cells results in anaemia;
* Fabhalta (iptacopan) used to treat haemolytic anaemia in adults with PNH and reduce kidney damage in patients with complement 3 glomerulopathy;
* Ixchiq, the first vaccine that protects against chikungunya;
* Qalsody (tofersen) for treating adults with a type of amyotrophic lateral sclerosis (ALS) caused by a mutation in the gene responsible for producing an enzyme called superoxide dismutase 1 (SOD1);
* Leqembi (lecanemab) for treating certain people with mild cognitive impairment and early Alzheimer's disease;
* Welireg (belzutifan) is a cancer medicine used to treat adults with advanced clear cell renal cell carcinoma and adults with von Hippel-Lindau (VHL) disease who need treatment for various cancers;
* Winrevair (sotatercept) used to improve the ability to exercise in adults with pulmonary arterial hypertension.
Most of these meds were also recently approved in Australia, with the main exception being Leqembi which had its rejection confirmed in Mar (PD 04 Mar). KB
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jun 25
